Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04206852 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of Balloon Pulmonary Angioplasty in China

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 37 years later May 11, 2028 → May 11, 2065
See other at-risk trials from Chinese Pulmonary Vascular Disease Research Group

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from May 11, 2028 to May 11, 2065
    • Enrollment increased: 200 → 1000 participants
    • Primary endpoints: details revised at 3 of 10 entries
    • Eligibility criteria expanded, about 6 words
  2. Primary endpoints: 9 to 10
    • Study description expanded, about 76 words
    v5
  3. Re-verified, no change to tracked fieldsv4
  4. Primary and study completion dates: May 11, 2022 to May 11, 2028
    • Primary endpoints: 8 to 9
    v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Balloon pulmonary angioplasty (BPA) is a potential treatment for patients with pulmonary artery stenosis, including non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH), takayasu arteritis and fibrosis mediastinitis. The aim of this study was to evaluate the safety and efficacy of BPA in CTEPH and patients not amenable to pulmonary endarterectomy(PEA) or suffered from persistent CTEPH after PEA, , takayasu arteritis and fibrosis mediastinitis.
Trial Details
NCT Number NCT04206852
Lead Sponsor Chinese Pulmonary Vascular Disease Research Group
Conditions
(from sponsor)		 Chronic Thromboembolic Pulmonary Hypertension
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov